A new analysis of clinical trial data shows the GLP-1 pill orforglipron promotes weight loss and reduces waist circumference in women regardless of their menopausal status.

A new analysis of the ATTAIN-1 and ATTAIN-2 clinical trials indicates that the GLP-1 medication orforglipron (Foundayo) helps women lose weight regardless of whether they are premenopausal, perimenopausal, or postmenopausal. Researchers found the pill effective for women with obesity or overweight, including those with type 2 diabetes, offering a potential alternative to injectable weight-loss treatments.

Study Methodology and Findings

The research analyzed data from two trials involving women with a BMI of 27 or higher who had at least one weight-related medical condition. Participants were divided into groups based on their menopausal status, with each group containing between 142 and 225 individuals. Over a 72-week period, those taking orforglipron lost an average of up to 14% of their body weight, compared to those taking a placebo. Beyond total weight loss, the study tracked changes in body composition. Participants saw waist circumference reductions of up to 12.5 centimeters, or about 5 inches. Additionally, up to 83% of women taking the medication lost at least 5% of their body weight, a threshold often associated with improvements in blood pressure, blood sugar, and cholesterol levels.

Clinical Perspectives on Treatment

Medical experts noted that the pill form of orforglipron offers convenience compared to injectable GLP-1 drugs, as it does not require refrigeration or needles. However, doctors emphasize that pharmacological treatment should be part of an individualized plan that includes nutrition and physical activity. Patients are advised to consult with physicians to determine the best treatment option based on effectiveness, tolerability, and personal health needs.